Innovative regenerative medicines in the EU: a better future in evidence?
about
Distributive justice and regenerative medicine.Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation.Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence.Advantages of Graphene Biosensors for Human Stem Cell Therapy Potency Assays.
P2860
Innovative regenerative medicines in the EU: a better future in evidence?
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Innovative regenerative medicines in the EU: a better future in evidence?
@ast
Innovative regenerative medicines in the EU: a better future in evidence?
@en
type
label
Innovative regenerative medicines in the EU: a better future in evidence?
@ast
Innovative regenerative medicines in the EU: a better future in evidence?
@en
prefLabel
Innovative regenerative medicines in the EU: a better future in evidence?
@ast
Innovative regenerative medicines in the EU: a better future in evidence?
@en
P2093
P2860
P1433
P1476
Innovative regenerative medicines in the EU: a better future in evidence?
@en
P2093
Andrew Webster
Mark S Corbett
Nerys Woolacott
Robert Hawkins
P2860
P2888
P356
10.1186/S12916-017-0818-4
P407
P577
2017-03-08T00:00:00Z
P6179
1083941587